Topics:
Genitourinary Cancers • Bladder Cancer • Medical Oncology • NCI-CCC Tumor Board Question • Urologic Oncology • Duke • NCI-CCC GU Tumor Board Question • Duke GU Tumor Board
For a patient who is cisplatin-eligible with localized, high-grade upper tract urothelial carcinoma, but no muscularis propria seen on biopsy, what is your approach?
What neoadjuvant or adjuvant therapy would you give?
Answer from: Medical Oncologist at Academic Institution
The risk of clinical under-staging is notorious in UTUC; therefore, we aim to maximize control of disease and address the meaningful risk of micro-metastasis. In that context and outside clinical trial option, we favor the use of neoadjuvant cisplatin-based chemotherapy using either dose dense MVAC ...
Sign in or Register to read more